Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Borg

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pathology|November 16, 2017
Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatmentCharlotta Hedner, David Borg, Björn Nodin, et al.
Journal of Translational Medicine|October 26, 2018
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinomaDavid Borg, Anna H Larsson, Charlotta Hedner, et al.
BMC Clinical Pathology|August 2, 2016
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinomaDavid Borg, Charlotta Hedner, Björn Nodin, et al.
BMC Clinical Pathology|October 17, 2009
Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumorMats Jönsson, Anna Ekstrand, Thomas Edekling, et al.
Frontiers in Oncology|November 16, 2020
Tumor-Associated CD68<sup>+</sup>, CD163<sup>+</sup>, and MARCO<sup>+</sup> Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal AdenocarcinomaMartin Jeremiasen, David Borg, Charlotta Hedner, et al.
Journal of Gastrointestinal Oncology|January 13, 2017
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinomaRichard Fristedt, David Borg, Charlotta Hedner, et al.
Biomarker Research|May 18, 2016
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinomaDavid Borg, Charlotta Hedner, Alexander Gaber, et al.
Annals of Surgical Oncology|July 28, 2023
Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide StudyAndrianos Tsekrekos, David Borg, Victor Johansson, et al.
Journal of Innate Immunity|May 3, 2022
High Infiltration of CD68+/CD163- Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric AdenocarcinomaMaria C Svensson, Maja Svensson, Björn Nodin, et al.
Oncoimmunology|June 9, 2021
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survivalMaria Christina Svensson, Albin Lindén, Jakob Nygaard, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pathology|November 16, 2017
Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatmentCharlotta Hedner, David Borg, Björn Nodin, et al.
Journal of Translational Medicine|October 26, 2018
Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinomaDavid Borg, Anna H Larsson, Charlotta Hedner, et al.
BMC Clinical Pathology|August 2, 2016
Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinomaDavid Borg, Charlotta Hedner, Björn Nodin, et al.
BMC Clinical Pathology|October 17, 2009
Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumorMats Jönsson, Anna Ekstrand, Thomas Edekling, et al.
Frontiers in Oncology|November 16, 2020
Tumor-Associated CD68<sup>+</sup>, CD163<sup>+</sup>, and MARCO<sup>+</sup> Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal AdenocarcinomaMartin Jeremiasen, David Borg, Charlotta Hedner, et al.
Journal of Gastrointestinal Oncology|January 13, 2017
Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinomaRichard Fristedt, David Borg, Charlotta Hedner, et al.
Biomarker Research|May 18, 2016
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinomaDavid Borg, Charlotta Hedner, Alexander Gaber, et al.
Annals of Surgical Oncology|July 28, 2023
Impact of Laparoscopic Gastrectomy on the Completion Rate of the Perioperative Chemotherapy Regimen in Gastric Cancer: A Swedish Nationwide StudyAndrianos Tsekrekos, David Borg, Victor Johansson, et al.
Journal of Innate Immunity|May 3, 2022
High Infiltration of CD68+/CD163- Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric AdenocarcinomaMaria C Svensson, Maja Svensson, Björn Nodin, et al.
Oncoimmunology|June 9, 2021
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survivalMaria Christina Svensson, Albin Lindén, Jakob Nygaard, et al.
Pageof 4